Guillaume Mouillet

Publication Activity (10 Years)

Years Active: 2018-2021
Publications (10 Years): 4

Top Topics

Randomized Controlled Trial

Top Venues

Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation

Health and quality of life outcomes

Cancer medicine

This page only lists publications with an associated author ORCID identifier.

Publications

Guillaume Mouillet, Antoine Falcoz, Joëlle Fritzsch, Hamadi Almotlak, Pascale Jacoulet, Xavier Pivot, Cristian Villanueva, Laura Mansi, Stefano Kim, Elsa Curtit, Nathalie Meneveau, Olivier Adotevi, Marine Jary, Guillaume Eberst, Angelique Vienot, Fabien Calcagno, Astrid Pozet, Oumelkheir Djoumakh, Christophe Borg, Virginie Westeel, Amélie Anota, Sophie Paget-Bailly
Feasibility of health-related quality of life (HRQoL) assessment for cancer patients using electronic patient-reported outcome (ePRO) in daily clinical practice. Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation 30 (11) (2021)
Guillaume Mouillet, Fabio Efficace, Antoine Thiery-Vuillemin, Emilie Charton, Mieke Van Hemelrijck, Francesco Sparano, Amélie Anota
Investigating the impact of open label design on patient-reported outcome results in prostate cancer randomized controlled trials. Cancer medicine 9 (20) (2020)
Guillaume Mouillet, Joëlle Fritzsch, Sophie Paget-Bailly, Astrid Pozet, Ikram Es-Saad, Aurelia Meurisse, Dewi Vernerey, Kristina Mouyabi, Diane Berthod, Franck Bonnetain, Amélie Anota, Antoine Thiery-Vuillemin
Health-related quality of life assessment for patients with advanced or metastatic renal cell carcinoma treated with a tyrosine kinase inhibitor using electronic patient-reported outcomes in daily clinical practice (QUANARIE trial): study protocol. Health and quality of life outcomes 17 (1) (2019)
Guillaume Mouillet, Marie-Justine Paillard, Tristan Maurina, Dewi Vernerey, Thierry Nguyen Tan Hon, Hamadi Almotlak, Ulrich Stein, Fabien Calcagno, Diane Berthod, Elise Robert, Aurelia Meurisse, Antoine Thiery-Vuillemin
Open-label, randomized multicentre phase II study to assess the efficacy and tolerability of sunitinib by dose administration regimen (dose modification or dose interruptions) in patients with advanced or metastatic renal cell carcinoma: study protocol of the SURF trial. Trials 19 (1) (2018)